



Studies in Natural Products Chemistry

Atta-ur-Rahman/Editor



Volume 31
Indices (Part A)

Studies in Natural Products Chemistry

Volume 31

Indices (Part A)

Edited by

Atta-ur-Rahman

*H.E.J. Research Institute of Chemistry,
University of Karachi, Karachi 75270, Pakistan*

2005



ELSEVIER

Amsterdam – Boston – Heidelberg – London – New York – Oxford
Paris – San Diego – San Francisco – Singapore – Sydney – Tokyo

ELSEVIER B.V.
Radarweg 29
P.O. Box 211, 1000 AE
Amsterdam, The Netherlands

ELSEVIER Inc.
525 B Street
Suite 1900, San Diego
CA 92101-4495, USA

ELSEVIER Ltd.
The Boulevard
Langford Lane, Kidlington,
Oxford OX5 1GB, UK

ELSEVIER Ltd.
84 Theobalds Road
London WC1X 8RR
UK

© 2005 Elsevier B.V. All rights reserved.

This work is protected under copyright by Elsevier B.V., and the following terms and conditions apply to its use:

Photocopying

Single photocopies of single chapters may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Permissions may be sought directly from Elsevier's Rights Department in Oxford, UK: phone (+44) 1865 843830, fax (+44) 1865 853333, e-mail: permissions@elsevier.com. Requests may also be completed on-line via the Elsevier homepage (<http://www.elsevier.com/locate/permissions>).

In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (+1) (978) 7508400, fax: (+1) (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) 20 7631 5555; fax: (+44) 20 7631 5500. Other countries may have a local reprographic rights agency for payments.

Derivative Works

Tables of contents may be reproduced for internal circulation, but permission of the Publisher is required for external resale or distribution of such material. Permission of the Publisher is **required** for all other derivative works, including compilations and translations.

Electronic Storage or Usage

Permission of the Publisher is required to store or use **electronically** any material contained in this work, including any chapter or part of a chapter.

Except as outlined above, no part of this work may be **reproduced, stored** in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, **without** prior written permission of the Publisher.

Address permissions requests to: Elsevier's Rights Department, at the fax and e-mail addresses noted above.

Notice

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

First edition 2005

Library of Congress Cataloging in Publication Data

A catalog record is available from the Library of Congress.

British Library Cataloguing in Publication Data

A catalogue record is available from the British Library.

ISBN: 0-444-51878-9

Ⓢ The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).
Printed in The Netherlands.

Working together to grow
libraries in developing countries

www.elsevier.com | www.bookaid.org | www.sabre.org

ELSEVIER

BOOK AID
International

Sabre Foundation

**Studies in
Natural Products Chemistry**

**Volume 31
Indices (Part A)**

Studies in Natural Products Chemistry
edited by Atta-ur-Rahman

- Vol. 1 Stereoselective Synthesis (Part A)
- Vol. 2 Structure Elucidation (Part A)
- Vol. 3 Stereoselective Synthesis (Part B)
- Vol. 4 Stereoselective Synthesis (Part C)
- Vol. 5 Structure Elucidation (Part B)
- Vol. 6 Stereoselective Synthesis (Part D)
- Vol. 7 Structure and Chemistry (Part A)
- Vol. 8 Stereoselective Synthesis (Part E)
- Vol. 9 Structure and Chemistry (Part B)
- Vol. 10 Stereoselective Synthesis (Part F)
- Vol. 11 Stereoselective Synthesis (Part G)
- Vol. 12 Stereoselective Synthesis (Part H)
- Vol. 13 Bioactive Natural Products (Part A)
- Vol. 14 Stereoselective Synthesis (Part I)
- Vol. 15 Structure and Chemistry (Part C)
- Vol. 16 Stereoselective Synthesis (Part J)
- Vol. 17 Structure and Chemistry (Part D)
- Vol. 18 Stereoselective Synthesis (Part K)
- Vol. 19 Structure and Chemistry (Part E)
- Vol. 20 Structure and Chemistry (Part F)
- Vol. 21 Bioactive Natural Products (Part B)
- Vol. 22 Bioactive Natural Products (Part C)
- Vol. 23 Bioactive Natural Products (Part D)
- Vol. 24 Bioactive Natural Products (Part E)
- Vol. 25 Bioactive Natural Products (Part F)
- Vol. 26 Bioactive Natural Products (Part G)
- Vol. 27 Bioactive Natural Products (Part H)
- Vol. 28 Bioactive Natural Products (Part I)
- Vol. 29 Bioactive Natural Products (Part J)
- Vol. 30 Bioactive Natural Products (Part K)
- Vol. 31 Indices (Part A)

FOREWORD

The present index volume comprises the contents of previous 30 volumes published in this series. I hope that it will allow the readers to readily extract the required information from any of these volumes. The volume comprises 4 separate indices, which are:

1. Cumulative General Subject Index
2. Cumulative Organic Synthesis Index
3. Cumulative Pharmacological Activity Index
4. Cumulative Biological Source Index

This separation into different indices should also facilitate the readers in respect of obtaining the information required.

I would like to express my thanks to Mr. Liaquat Raza and Ms Qurat-ul-Ain Fatima for their assistance in the preparation of the index. I am also grateful to Mr. Waseem Ahmad for the typing work and to Mr. Mahmood Alam for secretarial assistance.

Atta-ur-Rahman

Ph.D. (Cantab.), Sc.D. (Cantab.)

Director, H.E.J. Research Institute of Chemistry,
Chairman (Federal Minister), Higher Education Commission

CONTENTS

<i>Foreword</i>	v
Cumulative General Subject Index	3
Cumulative Organic Synthesis Index	871
Cumulative Pharmacological Activity Index	1007
Cumulative Biological Source Index	1225

Indices

CUMULATIVE GENERAL SUBJECT INDEX

VOLUMES 1-30

- A₁ adenosine agonists **25:265**
 somatostatin as **25:265**
 opiates as **25:265**
 A₁ and A_{2A}-adenosine **25:895**
 A₂-agonists **25:265**
 A-549 (human lung adenocarcinoma) **30:588**
 activity of (-)-deoxypodophyllo-
 toxin against **30:588**
 activity of (-)-yatein against **30:588**
 1AA oxidation **25:657**
 inhibitor of **25:657**
 AADC **30:380**
 activity of **30:380**
 deficiency of **30:380**
 in abnormal sleeping **30:380**
 in eye movement abnormalities **30:380**
 in feeding difficulties with
 esophagea reflux **30:380**
 C-Aalkylation **10:412**
 AAPM [(2,2'-azobis (2-amidino
 propane) dihydrochloride)] **26:763**
 Aargesin **26:241**
Aaronsohnia sp. **29:683**
 AB-1006 A9 **21:411**
 ABA **27:341,354**
 of 1'-methyl ether **27:341**
 photoisomerization of **27:354**
 [3',5,7-²H₆] ABA **27:353**
 Abamectin (avermectin B) **12:9**
 ABC-transporter family **21:158**
 Abdominal constriction test **30:207**
 activity of (-)-menthol in **30:207**
 Abdominal pain **30:203,205**
 use of ginseng root in **30:203**
 use of *Psycotria colorata* in **30:205**
 11(15→1)Abeataxan **20:80,100,101**
 (3→20)Abeataxan **20:80,106**
 25-(10→9)Abeo-26(8→15) abeo-
 9β,14β,15α-olean-5-ene-3β,29-diol
 5:744,748,750
 19(4→3)-Abeo-8α,13(S)-epoxylabda-
 4(18),14-diene **29:102**
 activity in EBV bioassay system
 29:102
 9(10→19)Abeo-diene steroidal alkaloids
 2:205,206
Abernaemontana penduliflora **28:234**
 Aberrant crypt foci (ACF) **25:65**
Abies amabilis **22:391**
Abies balsamea **22:384**
 from balsam **22:384**
Abies grandis **22:391**
Abies koreana **20:619**
Abies mariesii **20:619**
Abies marocana **29:99**
 Abiesen **20:283**
 Abiesenonic acid **25:60**
 methyl ester **25:60**
 19-nor-Abieta-4(18),8,11,13-tetraen-7-
 one **29:100**
 activity in EBV assay system
 29:100
Ent-Abieta-8(14),13(15)-dien-16,12-
 olide (jolkiolide E) **9:283,284,290**
 Abieta-8,11,13-trien-7-one **29:99**
 activity in EBV assay system
 29:99
 18-nor-Abieta-8,11,13-triene-4α,7α,15-
 triol **29:99**
 activity in EBV assay system
 29:99
 Abieta-8,11,13-triene-7α,15,18-triol
 29:99
 activity in EBV assay system
 29:99
 Abieta-8,11,13-triene-7α,15,18-triol 7-
 acetate **29:99**
 activity in EBV assay system
 29:99
 Abietane **9:297**
 Abietane diterpenoids **20:660-680;**
 23:682
 Abietatriene **2:402,403**

- Abietatriene-6-one 14:669,670,673, 674,676
- Abietic acid 29:99,188
 activity in TPA assay system 29:99
 activity in CRG assay system 29:99
 pisiferic acid synthesis from 29:188
- Abiotic stress 23:741
- Abisapogenol 25:95
- Abnormal Beckmann rearrangement 16:133
- 4-AboA 27:193,203,204,225
 formation of 27:204
- Abramov reaction 6:353
- Abri Herba 25:99
 antihepatotoxic effect of Ogs from 25:99
- Abrisapogenol A 25:96
- Abrisapogenol B 25:96
- Abrisapogenol C 25:96
- Abrisapogenol D 25:96
- Abrisapogenol F 25:97
- Abrisapogenol I 25:97
- Abrisapogenol L 25:96
- Abrisaponin 25:97
- Abrisaponin A 25:96
- Abrisaponin C 25:96
- Abrisaponin D₂ 25:96
- Abrisaponin D₃ 25:96
- Abrisaponin D₁ 25:96
- Abrisaponin I 25:97
- Abrisaponin L 25:96
- Abrisaponin SB 25:95
- Abrisaponin SO₁ 25:95
- Abrus cantaniensis* 25:93
- Abrus fruticosus* 15:26;27:15
 abrusoside A from 27:15
 abrusoside B from 27:15
 abrusoside C from 27:15
 abrusoside D from 27:15
- Abrus precatorius* 7:152,15:25; 21:674;22:510;25:93;27:15,27
 abrusoside A from 27:15,27
 abrusoside B from 27:15,27
 abrusoside C from 27:15,27
 abrusoside D from 27:15,27
 abrusoside E from 27:15,27
 cycloartane from 21:674
 for epilepsy 22:510
- Abrus* sp. 25:180
- Abrusogenic acid 7:152
- Abrusoside A 27:15,27,28
 structure of 27:28
- Abrusoside B 27:15,27,28
 structure of 27:28
- Abrusoside C 27:15,27,28
 structure of 27:28
- Abrusoside D 27:15,27,28
 structure of 27:28
- Abrusoside E 27:15,27,28
 structure of 27:28
- Abscisic acid 25:367;27:330,331,322, 335,337,352,388
 activity of 27:331
 biological activity of 27:332
 conformations of 27:335
¹H-NMR spectra of 27:339
 metabolic inactivation of 27:322
 NOE experiment of 27:338
 structure of 27:321
 utility of 27:331
- (-)-Abscisic acid 27:346
 formation of 27:346
- (+)-Abscisic acid 27:346
 formation of 27:346
- Abscisic acid analogs 27:321,323-329
 activity of 27:483
- Abscisic acid ring 27:336,338
 interconversion of 27:336
- Abscisic acid-GE 27:354
 hydrolysis of 27:354
- Abscisic aldehyde 27:321
 in biosynthesis 27:321
- Absidia* sp. 25:160
- Absinthin (guaine sesquiterpene dimer) 29:574
 effects on HIV-1 protease 29:574
- Absintholide (guaine sesquiterpene dimer) 29:574
 effects on HIV-1 protease 29:574
- Absolute configuration 9:27
 by CD procedure 9:27
 by Horeau procedure 9:25,26
 by Nakanishi's method 2:89

- in 24-(β -hydroxyethyl)-in 24-(carboxy-methyl) steroids 15:79-81
- in 24-ethyl-26-hydroxysteroids 15:84
- in 24-hydroxymethyl steroids 15:79
- in 24-hydroxysteroids 15:76,77
- in 24-methyl-25,26-dihydroxysteroids 15:84-86
- in 24-methyl-26-hydroxy and 24-methyl-26-oic steroidal side-chains 15:81-84
- in 26-hydroxysteroids 15:77,78
- of (+)-aristoserratine 11:296
- of (+)-monomoriwei 6:449,450
- of (-)-hobartine 11:290
- of (-)-peduncularine 11:284
- of 3 α ,13-dihydroxy-11-epiapotrichothecenes 13:520
- of amphotericin B 6:231
- of aureol 9:31
- of benzo [a] pyrene oxide 7:8,14
- of carotenoids 7:321
- of decaprenoxanthin 7:355
- of liverwort sesquiterpenoids 18:607-646
- of Mosher's esters 13:77
- of penems 4:435
- of phoracantholide I,J 6:546
- of quinocarcin 10:126
- of *R,S*-4-hydroxycyclopentenones 6:315
- of sclerosporin 6:549-551
- of sigmosceptrellins A-C 9:16
- of solenopsin B 6:430
- of sugars saponins 15:190
- of taxol 11:3,7
- of thienamycin 4:433,436
- of urdamycin A 11:134
- Absolute stereostructure 28:11
- of broussonetine C 28:11
- of broussonetine L 28:12
- ABTS (2,2'-azino-bis-(3-ethylthiazoline-6-sulfonic acid) 26:1014,1015,1020
- oxidation of 26:1016
- Abyssinian tea 23:653
- (2*S*)-Abyssinone II 28:17
- as aromatase inhibitor 28:17
- Acacetin (5,7-dihydroxy-4'-methoxy-flavone) 29:571
- inhibition of HIV-1 protease 29:571
- Acacia astringens* 7:427
- Acacia auriculiformis* 21:674;23:487,498;26:467
- triterpenoid saponin from 21:674
- Acacia catechu* 29:678,680
- Acacia confusa* 29:603
- Acacia honey* 28:386
- aroma of 28:386
- Acacia melanoxylon* 27:838
- Acacia nilotica* 7:427;26:358
- Acacia* spp. 29:582
- Acacia tomentosa* 7:427
- Acaciamine 23:498
- Acaciaside A 21:674;23:497
- Acaciaside AB 26:467
- Acaciaside B 21:674;23:497
- Acaciaside C 23:497
- Acalycigorgia inermis* 5:370
- Acalycigorgia* sp. 5:368,369
- Acalypha fruticosa* sk. 22:510
- for epilepsy 22:510
- Acalypha fruticosa* Forsk. 22:510
- for epilepsy 22:510
- Acanthacerebroside A 18:481
- Acanthaster planci* 7:288
- acanthaglycosides A-D,F from 7:288
- marthasteroside A from 7:288
- thornasteroside A from 7:288
- Acanthella acuta* 21:329;25:848,852,853
- Acanthella aurantica* 21:270
- Acanthella cavernosa* 21:351,353,355,356,359,361,365-367;25:689,858;26:465;28:663
- 10-*epi*-isokalihinol H from 28:663
- 15-isothiocyano-1-*epi*-kalihinene from 28:663
- Acanthella klethra* 20:525;25:848,852;26:810;28:662
- isothiocyanoates from 28:662
- Acanthella pukherrina* 25:853;28:660
- isothiocyanoates from 28:660
- sesquiterpenes from 28:660

- Acanthella pulcherrima* 25:852
Acanthella sp. 21:334;25:852,853;
 28:663
 kalihinol G of 28:663
 kalihinol H of 28:663
Acanthenes A-C 21:334
Acanthicifoline 7:191
Acanthifolicin 5:384;28:710;25:832
 episulfide group of 28:710
Acanthodendrilla sp. 25:704;28:702
 acanthosterol sulfate A of 28:702
 acanthosterol sulfate B of 28:702
 acanthosterol sulfate C of 28:702
 acanthosterol sulfate D of 28:702
 acanthosterol sulfate F of 28:702
 acanthosterol sulfate G of 28:702
 acanthosterol sulfate H of 28:702
 acanthosterol sulfate I of 28:702
 acanthosterol sulfate J of 28:702
 antifungal activity of 28:702
Acanthodris nanaimoensis 19:139
Acanthoic acid 29:103
 activity in TNF α bioassay system
 29:103
Acantholippia seriphioides 21:618
Acanthomyops claviger 6:454
Acanthopanax koreanum 29:103
Acanthophyllum gypsophiloides 26:3
Acanthophyllum squarrosum 24:149;
 26:31,50,55
 squarroside A from 26:31
Acanthophyllum squarrosum 26:55
 immunomodulatory effect of
 26:55
Acanthoscelides obtectus 10:160
Acanthosterol sulfate A-J 25:704
Acanthus ebracteatus 7:176
Acanthus illicifolius 7:176,179,181,182,
 189-191,193
Acanthus mollis 27:188,191
Acarapis woodi 28:387,390
 in honey bees' tracheal tubes
 28:387
 infestations in Minnesota 28:390
Acarbose 13:3
 as α -amylase inhibitor 13:3
 as α -glucosidase inhibitors 7:47
 as antihyperglycemic drug
 10:505
 as antihyperlipoproteinaemic
 drug 10:505
Acaria saxatilis 22:634
 Acaricidal activities 24:799;28:403,406,
 412,422
 against *Dermatophagoides*
 pteronyssinus 28:422
 against *Psoroptes cuniculi*
 28:412
 against *Rhipicephalus*
 appendiculatus 28:406
 for killing adult ticks 28:403
 of caffeine 28:422
 of *Cuminum cyminum* 28:427
 of essential oils 28:412,427
 of *Eucalyptus camaldulensis*
 28:427
 of eugenol 28:403
 of extract prepared by microwave
 assisted process (MAP) 28:427
 of *Lavandula angustifolia*
 28:412
 of linalool 28:412
 of *Margaritaria discoidea*
 28:406
 of *Origanum syriacum* var.
 bevanii 28:427
 of phenylpropanoid derivatives
 28:403
 of *Pimenta dioica* 28:403
 of *Pimpinella anisum* 28:427
 of *Tanacetum vulgare* extracts
 28:427
 of β -thujone 28:427
 Acaricidal properties 28:400,406
 of benzaldehyde 28:406
 of carvacrol 28:406
 of cedrene 28:406
 of α -cyclocitral 28:406
 of β -cyclocitral 28:406
 of *Euphorbia obovalifolia* latex
 28:400
 of *Ficus brachypoda* latex
 28:400
 of geraniol 28:406
 of (*E*)-geranylacetone 28:406
 of α -ionone 28:406

- of linalool 28:406
- of *m*-cymene 28:406
- of methyl salicylate 28:406
- of nerol 28:406
- of nerolidol 28:406
- of nonanal 28:406
- of β -ocimene 28:406
- of phenylacetaldehyde 28:406
- of phenylacetone nitrile 28:406
- of α -terpineol 28:406
- Acaricide 28:381,429,435
 - cross-resistance of 28:429
- Acarnus bergquistae* 25:724
- Acarus siro* 28:382,423
 - as mite sp. 28:382
- Acarviosin 22:177
- Acarviosine 10:503,504,506
- Accedine 5:125
- Accedinine 5:125
- Accedinisine 5:125
- Acer nikoense* 26:889,895,899
- Acer saccharum* 25:666
- Acer* sp. 21:502;26:905
- Acernicoense* 17:358,367-368,375
- Acerogenin A 17:367,375;20:276
- Acerogenin A-L 26:899
- Acerogenine-E 17:368
- Acerolide 23:175
- Aceroside I 17:367
- Aceroside IV 17:367
- Aceroside V 17:367
- Aceroside VII 17:358
- Aceroside XI 17:368;26:895
- Acerosterol 23:177
- Acesulfame-K 15:4
- Acetal 6:336
- Acetaldehyde dependent aldolase (DERA) 30:428
- Acetalization 1:584
- trans*-Acetalization 4:325,326,331,338,339,495
- 6-Acetamido-2,3,4-tri-*O*-allyl-6-deoxy- α -glucoheptopyranosiduronic acid 11:434,435
- 2-Acetamido-2-deoxy-*D*-glucopyranose 6:351
- 2-Acetamido-2-deoxy-*D*-glucopyranosides 6:389
- 2-Acetamido-2-deoxyglucomannans 5:286,287
- 5-Acetamido-3,5-dideoxy-*D*-glycero-*D*-galacto-2-nonulosonic acid 30:420
- 2-Acetamidofluorene 26:1003
- p*-Acetamidophenyl-1,4,4'-dithiocellotrioside 8:351
- p*-Acetamidophenyl-1,4-dithiocellobioside 8:350,351
- 14-Acetamidosanantonin 24:124,125
- Acetaminophen 26:257;30:192
 - as analgesic/antipyretic 30:192
- Acetaminophenone 25:219,614
- Acetate/mevalonate pathway 25:130
- Acetobacter suboxydans* 17:636-637
- Acetobromoglucose 10:366,367
- β -Acetochloromannose 8:321,322
- Acetogenic cyclic peroxides 9:18
- Acetogenins 9:385,391,392,395,397-399,403;18:193-227;19:81
- Acetolysis 30:489
- (-)-Acetomycin 10:443
 - antimicrobial activity of 10:443
 - antitumor activity of 10:444,447
- (+)-5-*epi*-Acetomycin 10:447
 - antitumor activity of 10:447
- Acetonide 14:160;19:489
- Acetonitrile 22:205
- Acetonylbutanolides 17:273
- Acetophenone 2:169,170;25:666
- Acetophenone phenylhydroazone 9:581
- 3-Acetoxy monomethyl phthalates 14:5
- 19-Acetoxy-11-methoxytabersonine 2:375
- 3 β -Acetoxy-11-ursen-13 α ,30-olide 654,656
 - IR spectrum of 30:654
 - NMR spectroscopic data of 30:654
 - structure of 30:656
- 16-Acetoxy-12-*O*-acetyl-horminone 15:169,170,173
- 2 α -Acetoxy-14-hydroxy-15-iso-valeroloxo-9-oxo-costunolide 29:89
 - activity in NF κ B assay system 29:89
 - activity in TNF α assay system 29:89

- (15*R*)-15-Acetoxy-15,20-dihydro-catharanthine **14:815**
- 20-Acetoxy-15,20-dihydrocatharanthine **4:32**
- (15*S*)-15'-(Acetoxy-20'-deoxy-vinblastine **14:815,816**
from (15*R*)-15-acetoxy-15,20-dihydro catharanthine **14:815,816**
- 1 α -Acetoxy-20 α_F -hydroxy-24 α ,25 α -epoxywitha-5-ene-22,26-olide-4 β -O-glucopyranoside **20:191**
- 22-Acetoxy-23,24-dinorchola-1,4,6-trien-3-one **11:398**
- (+)-1-Acetoxy-2-epipinoresinol **5:538-540**
- 1 α -Acetoxy-2 α ,6 β ,9 β -trifuroyloxy-4 β -hydroxy-dihydro- β -agarofuran **29:87**
- 4-Acetoxy-3[1'-*tert*-butyldimethylsilyloxy) ethyl]-2-azetidinone **4:448**
- 20*S*-Acetoxy-3 β -16-dihydroxylanost-7-en-18-oic acid-18,16-lactone **7:269**
- 3-Acetoxy-4-hydroxybenzaldehyde **8:166,167**
- 9 α -Acetoxy-4 β ,15-epoxymiller-1(10)-Z-enolide **29:89**
activity in NF κ B assay system **29:89**
- 2*R*, 3*R*-(+)-3-Acetoxy-5,7,4'-trihydroxy-flavanone **27:34,35**
structure of **27:35**
- Acetoxy-5,7-dihydroxy-4'-methoxy flavanone **27:34,35**
structure of **27:35**
- (+)-1-Acetoxy-6-epipinoresinol **5:538-540**
- 8 α -Acetoxy-6-*epi*-tannunolide A **27:583**
- 1-Acetoxy-6 α -hydroxy-germacran-1(10), 3(4)-dien-8,12-olide **27:561**
- 16-Acetoxy-7,8-epoxy-3,12-dolabelladien-13-one **20:491**
- 2-Acetoxy-8,13-dihydroxy-11-*epi* APO **13:522**
- 12-Acetoxy-8,13-dihydroxy-11-*epi*-apotrichothec-9-ene **9:20**
- 7 β -Acetoxy-8,13-epoxy-1 α ,6 β ,9 α -trihydroxylabd-14-en-11-one **25:256**
- 1 β -Acetoxy-8 β -hydroxyeudesm-4(15), 7-diene-8-12-olide **20:660**
- 3 β -Acetoxy-8 β -isobutyryloxy-reynosin **29:87**
activity in Mam-2 assay system **29:87**
activity in DIF assay system **29:87**
- 15-Acetoxy-9 α -hydroxy-8 β -methacryloyloxy-14-oxo-acanthospermolide **29:89**
activity in NF κ B assay system **29:89**
- 15-Acetoxy-9 α -methacryloyloxy-8 β -hydroxy-14-oxo-acantho-spermolide **29:89**
activity in NF κ B assay system **29:89**
- 5-Acetoxyarctigenin monoacetate **18:601**
- 6'-Acetoxyavarol **15:301**
- 1-Acetoxybutadiene **1:571**
- 1'-Acetoxychavicol acetate **23:800**
- 25-Acetoxycholesta-1,4,6-trien-3-one **11:385**
- 2 α -Acetoxycholestanone **18:888**
- 2 β -Acetoxycholestanone **18:888**
- 3-Acetoxycostunolide **29:89**
activity in NF κ B assay system **29:89**
- (+)-Acetoxycrenulide **18:22-28**
- 15-Acetoxy-eremantholide B **29:89**
activity in NF κ B assay system **29:89**
activity in TNF α assay system **29:89**
- 1'-Acetoxyeugenol **23:800**
- 12-Acetoxyfarnesol acetate **27:586**
- 3-Acetoxyflavanones **30:729**
structure of **30:729**
- α -Acetoxyfuranone **12:14**
- 3-Acetoxyguaiazulene **14:321**
- 23*S*-Acetoxyholost-7-en-3 β -ol **7:273**
- 6 β -Acetoxyholosta-7,24-dien-3 β -ol **7:275**

- 23*S*-Acetoxymalabarica-7,25-dien-3 β -ol
7:273
- 16 α -Acetoxymalabarica-7-en-3 β -ol 7:277
- 1-Acetoxymalabarica 3:6,60
- 6-Acetoxymalabarica-14(26),17*E*,21-triene 27:168
- 3 β -Acetoxymalabarica-14(26),17*E*,21-triene 27:591
- ent*-13-*epi*-12 α -Acetoxymalabarica oxide
25:273
- 10-Acetoxymalabarica 25:160
- 6-Acetoxymethyl-2,6-dimethyl-9-methoxy tricyclo [5.3.0^{1,5}] undec-9-en-8,11-dione 8:163
- 5-Acetoxymethyltrachelogenin 18:602
- 5-Acetoxymethyltrachelogenin monoacetate 18:602
- 9 α -Acetoxymiller-1(10)-*Z*-enolide
29:89
activity in NF κ B assay system
29:89
- 13-Acetoxymodhephenene 3:6,61
- 18-Acetoxy-N_a-deacetylisorretuline
1:38-39
- 18-Acetoxy-norfluorocurarine 1:38-39
- (+)-1-Acetoxy-pinoreosinol- β -D-glu
26:200
- (+)-1-Acetoxy-pinoreosinol 5:523,533,
538,544;26:200
- (+)-Acetoxy-pinoreosinol dimethyl ether
26:241
as PAF-induced inhibitor 26:241
- (+)-1-Acetoxy-pinoreosinol-4"-O-methyl
ether 5:523,533-535
- (+)-1-Acetoxy-pinoreosinol-4"-O-methyl
ether-4'- β -D-glucoside 5:523
- (+)-1-Acetoxy-pinoreosinol-4'- β -D-
glucoside 5:523
- 6 β -Acetoxy-pseudotropanol 21:751
- 3-Acetoxy-pyrrol-2(5H) -one 13:117,
118
- (+)-16 α -Acetoxytabersonine 2:186
- 8 α -Acetoxy-tannunolide E 27:585
- 5-Acetoxytrachelogenin diacetate
18:601
- 6 β -Acetoxy-tropanone 21:751
- 6 α -Acetoxyvouacapan-17,7 β -lactone
29:103
activity in AOS bioassay system
29:103
- β -Acetoxy- α -diazoesters 30:447
reaction of 30:447
- 15-Acetylcardiopetamine 26:869
- N*-Acetyl cysteamine 13:496
- Acetyl pyrazine 13:320
- β -Acetyl alcohol 14:462
- Acetyl CoA carboxylase 25:525
- 3-Acetyl deoxynivalenol 13:520,521,
536
- N*-Acetyl glucosamine 7:31,47,49
- β -(1-3)-*N*-Acetyl glucosaminyl-
transferase 10:484
- N*-Acetyl isomuramic acid 6:386,387
- O*-Acetyl isophotosantonic lactone
14:357
- Acetyl kaikasaponin 25:95
- N*-Acetyl muramic acid 7:31,47,49
- N*-Acetyl neuraminic acid (NANA)
13:207-210
- O*-Acetyl normacusine B 13:386
- O*-Acetyl preperakine 13:387
- O*-Acetyl villamine 13:396
- 2-*O*-Acetyl-(*S*)-(+)-mandelic acid
13:468,469
- N_a-Acetyl-11,12-dihydroxyaspidos-
permatine 1:40
- N_a-Acetyl-11-hydroxyaspidos-
permatidine 1:40
- Acetyl-11-keto- β -boswellic acid (triter-
pene) 29:585
effects on LELA 29:585
- 6-*O*-Acetyl-2,3,4-tri-*O*-benzyl-*D*-
glucono-1,5-lactone 12:335
- 3-Acetyl-2,6-dimethylpyridin-4-one
13:545
- 7'-Acetyl-2-methoxypicropodophyllin
30:586
- 2-Acetyl-3,5-dihydroxy-1-geranoxy-6-
methyl-4-(2-methyl)butyryl-benzene
30:615
structure of 30:615
- 3-Acetyl-4,6-dimethylpyridin-2-one
13:545
- 1-*O*-Acetyl-4-methoxyglycorine 26:100,
615

- acetylation of secologanin 26:100,615
- (7*R*,8*S*,7'*R*,8'*R*)-(+)-7'-Acetyl-5'-methoxypicropodophyllin 30:586
 - ¹³C NMR comparison of 30:586
 - circular dichroism (CD) spectrum of 30:586
 - ¹H NMR comparison of 30:586
 - HREIMS of 30:586
 - molecular formula of 30:586
 - ROESY correlation of 30:586
 - ROESY NMR of 30:586
 - stereochemistry of 30:586
- 4-Acetyl-6,8-dihydroxy-5-methyl-3,4-dihydroisocoumarin 15:409
- 17-*O*-Acetylajmaline 9:183-185
- Acetylamino-1,2-dihydroacronycine 20:800
- 2-Acetylamino-3*H*-phenoxazin-3-one 27:219
 - structure of 27:219
- 5-Acetylamino-6-formyl amino-3-methyluracil 22:5
- Acetylaminoanthraquinone 9:437
- Acetyl-andromedol 20:27
- Acetylannulatophenonoside 30:624
- N*_n-Acetylaspidospermatidine 1:40
- Acetylastergaloside I 25:193
- 3-Acetylated flavanones 798
- Acetylation 19:480
 - of *syn* alcohol 19:480
- β-Acetylation procedure 10:447
 - for acetomycin synthesis 10:447
 - stereoselective 10:447
- Acetylation reaction 23:172
 - of tobacgolide 23:172
- 2-Acetylbutyrolactone 8:284,285
- Acetylcholine 22:15,29;25:516,519,520,527,530,547
 - nicotinic receptor for 25:519
 - vasodilator effect of 25:595
- Acetylcholine esterase 22:16
- Acetylcholine receptor 18:863
- Acetylcholine-gated Na⁺/K⁺ channels 25:527
- Acetylcholinesterase 7:18
- Acetylcholinesterase inhibitors 21:585
- Acetyl-coenzyme A 7:112
- (±)-*N*-Acetylcolchicinol 29:376
 - allocolchicinoids total synthesis of 29:376
- 19-Acetylcorrin 9:600,601
- 3-Acetylcoumarins 368
- 2-*O*-Acetyl-*D*-glucal tetraacetate 10:414
- (+)-Acetyl domesticine 16:519
- Acetylenation 1:611,612
 - of acetals diastereoselective 1:611,612
- Acetylene-C-glycosides 10:359
- Acetylenes 23:341
- α,β-Acetylenic alcohols 4:493
- Acetylenic compounds 30:706
- C-Acetylenic hexopyranose 10:374
- Acetylenic oxy-Cope rearrangement 8:250
- 3-*O*-Acetylerythrodil 25:59
- 2'-Acetylglaucaurubinone 7:379,380
- N*-Acetylglucosamine 1:417
- Acetylglucosamine 30:95
 - molecular weight of 30:95
- β-*N*-Acetylglucosaminidases 12:346
- β-(1-6)-*N*-Acetylglucosaminyl-transferase 10:486
 - in biosynthesis of I-antigens 10:486
- 3-Acetylgoniotriol 9:394
- (+)-8-Acetylgonioitriol 19:463
- 8-Acetylharpagide 29:83
 - activity in EBV, liver-1, lung-2, skin-1, skin-4 assay systems 29:83
- Acetyl-histamines 15:328
- Acetyl-horminone 20:670
- N*-Acetyliscodonocarpine 9:73-75,77
- O*-Acetyl-isopseudolycorine 26:614
- O*-Acetylisoretuline 1:38,39
- N*-Acetyllactosamine (2-acetamido-2-deoxy-4-*O*-β-*D*-galactopyranosyl-α-*D*-glucose) 10:459,461-467
- 3-Acetyllephtophylline-A 20:486,487
- 1-*O*-Acetyllycorine 26:615
- Acetylmelodorenol 9:400,152
- N*-Acetyl-muramyl-(*L*)-alanyl-(*D*)-isoglutamine(MPD) 13:210-212